Skip to main content
. Author manuscript; available in PMC: 2023 Jul 25.
Published in final edited form as: ACS Chem Biol. 2022 Jun 24;17(7):1789–1798. doi: 10.1021/acschembio.2c00145

Figure 1: JCS-1 degrades endogenous DcpS in AML cell lines:

Figure 1:

A) Chemical structures of RG3039 (DcpS inhibitor), JCS-1 (active PROTAC), and JCS-2 (inactive epimeric control PROTAC). B) JCS −1 degrades DcpS in a dose-dependent manner in MOLM-14 cells. Cells were treated for 24 hours. Blots show lysates from independent wells harvested side-by-side on the same day. Quantified data represents the mean ± SD from three independent biological replicates. One-way ANOVA, *** p < 0.005; **** p < 0.001